Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of “Buy” from Brokerages

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have been given a consensus recommendation of “Buy” by the six research firms that are presently covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $23.80.

Several equities research analysts have recently issued reports on LXEO shares. Chardan Capital raised their target price on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Leerink Partners dropped their target price on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Wednesday, November 13th. HC Wainwright increased their price target on Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $24.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday.

Lexeo Therapeutics Stock Up 14.5 %

Shares of LXEO opened at $5.61 on Friday. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The business has a fifty day moving average of $6.71 and a 200 day moving average of $9.31. The company has a market cap of $185.52 million, a PE ratio of -1.78 and a beta of 3.08. Lexeo Therapeutics has a 52-week low of $4.67 and a 52-week high of $19.50.

Institutional Trading of Lexeo Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of LXEO. BNP Paribas Financial Markets increased its holdings in Lexeo Therapeutics by 184.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares during the period. Values First Advisors Inc. purchased a new position in shares of Lexeo Therapeutics during the third quarter valued at $67,000. SG Americas Securities LLC bought a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at about $72,000. JPMorgan Chase & Co. lifted its stake in Lexeo Therapeutics by 135.6% in the third quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock worth $93,000 after acquiring an additional 5,915 shares during the period. Finally, MetLife Investment Management LLC grew its holdings in Lexeo Therapeutics by 121.5% during the 3rd quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock worth $129,000 after acquiring an additional 7,803 shares in the last quarter. Institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.